Cytotoxic-T-lymphocyte human papillomavirus type 16 E5 peptide with CpG-oligodeoxynucleotide can eliminate tumor growth in C57BL/6 mice

被引:49
作者
Chen, YF
Lin, CW
Tsao, YP
Chen, SL [1 ]
机构
[1] Natl Def Med Ctr, Dept Microbiol & Immunol, Taipei, Taiwan
[2] Chang Gung Mem Hosp, Dept Ophthalmol, Taoyuan, Taiwan
[3] Chang Gung Univ, Taoyuan, Taiwan
关键词
D O I
10.1128/JVI.78.3.1333-1343.2004
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Previously, we identified human papillomavirus type 16 (HPV-16) E5 as a tumor rejection antigen that can induce cytotoxic T lymphocytes (CTLs) to protect against tumor growth (D. W. Liu et al., J. Virol. 74:90839089, 2000). In the present study, we further mapped the CTL epitope of E5 protein by analyzing E5-specific CD8(+) gamma interferon-positive (IFN-gamma(+)) double-positive cells in C57BL/6 mice with How cytometry. The results showed the region spanning amino acids 25 to 33 (VCLLIRPLL) contained the potential D-b-restricted CTL epitope. Subsequently, to determine whether peptide E5 25-33-based vaccination could induce E5-specific CTL activity, syngeneic animals received E5 25-33 emulsified with either CpG oligodeoxynucleotide (CpG ODN 1826) or Freund's adjuvant, and the growth of the tumors was monitored. The results showed that although both adjuvants induced E5-specific CD8(+) IFN-gamma(+) T cells and eradicated E5-containing tumor growth, CpG ODN was found to stimulate stronger CTL response than Freund's adjuvant. We also compared the immune response of the effector/memory/recall phase induced by E5 25-33 peptide or by E5 protein that was synthesized in vivo by adenovirus-based E5 gene delivery.,E5 25-33 peptide plus CpG ODN was shown to be a superior vaccine compared to the adenovirus-based E5 gene. Interestingly, their chronological patterns of immune response were similar, suggesting that E5 25-33 is a major CTL peptide of E5 protein.
引用
收藏
页码:1333 / 1343
页数:11
相关论文
共 72 条
  • [21] Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model
    Greenstone, HL
    Nieland, JD
    de Visser, KE
    De Bruijn, MLH
    Kirnbauer, R
    Roden, RBS
    Lowy, DR
    Kast, WM
    Schiller, JT
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (04) : 1800 - 1805
  • [22] DEPLETION OF CD4+ T-CELLS IN MAJOR HISTOCOMPATIBILITY COMPLEX CLASS-II DEFICIENT MICE
    GRUSBY, MJ
    JOHNSON, RS
    PAPAIOANNOU, VE
    GLIMCHER, LH
    [J]. SCIENCE, 1991, 253 (5026) : 1417 - 1420
  • [23] IDENTIFICATION OF THE E5 OPEN READING FRAME OF HUMAN PAPILLOMAVIRUS TYPE-16
    HALBERT, CL
    GALLOWAY, DA
    [J]. JOURNAL OF VIROLOGY, 1988, 62 (03) : 1071 - 1075
  • [24] Mechanism and function of a newly identified CpG DNA moth in human primary B cells
    Hartmann, G
    Krieg, AM
    [J]. JOURNAL OF IMMUNOLOGY, 2000, 164 (02) : 944 - 952
  • [25] Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo
    Hartmann, G
    Weeratna, RD
    Ballas, ZK
    Payette, P
    Blackwell, S
    Suparto, I
    Rasmussen, WL
    Waldschmidt, M
    Sajuthi, D
    Purcell, RH
    Davis, HL
    Krieg, AM
    [J]. JOURNAL OF IMMUNOLOGY, 2000, 164 (03) : 1617 - 1624
  • [26] HOWLEY PM, 1991, CANCER RES, V51, pS5019
  • [27] THE HPV16 E5 PROTEIN - EXPRESSION, DETECTION, AND STABLE COMPLEX-FORMATION WITH TRANSMEMBRANE PROTEINS IN COS CELLS
    HWANG, ES
    NOTTOLI, T
    DIMAIO, D
    [J]. VIROLOGY, 1995, 211 (01) : 227 - 233
  • [28] KAST WM, 1994, J IMMUNOL, V152, P3904
  • [29] DETECTION OF E5 ONCOPROTEIN IN HUMAN PAPILLOMAVIRUS TYPE 16-POSITIVE CERVICAL SCRAPES USING ANTIBODIES RAISED TO SYNTHETIC PEPTIDES
    KELL, B
    JEWERS, RJ
    CASON, J
    PAKARIAN, F
    KAYE, JN
    BEST, JM
    [J]. JOURNAL OF GENERAL VIROLOGY, 1994, 75 : 2451 - 2456
  • [30] KOLLER BH, 1990, SCIENCE, V248, P1227, DOI 10.1126/science.2112266